|
1
|
Aguiar RC, Yakushijin Y, Kharbanda S,
Salgia R, Fletcher JA and Shipp MA: BAL is a novel risk-related
gene in diffuse large B-cell lymphomas that enhances cellular
migration. Blood. 96:4328–4334. 2000.PubMed/NCBI
|
|
2
|
Takeyama K, Aguiar RC, Gu L, He C, Freeman
GJ, Kutok JL, Aster JC and Shipp MA: The BAL-binding protein BBAP
and related Deltex family members exhibit ubiquitin-protein
isopeptide ligase activity. J Biol Chem. 278:21930–21937. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hakmé A, Huber A, Dolle P and Schreiber V:
The macroPARP Genes Parp-9 and Parp-14 are developmentally and
differentially regulated in mouse tissues. Dev Dyn. 237:209–215.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan Q, Dutt S, Xu R, Graves K, Juszczynski
P, Manis JP and Shipp MA: BBAP monoubiquitylates Histone H4 at
Lysine 91 and Selectively modulates the DNA damage response. Mol
Cell. 36:110–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thang ND, Yajima I, Kumasaka MY, Iida M,
Suzuki T and Kato M: Deltex-3-like (DTX3L) stimulates metastasis of
melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget.
6:14290–14299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Sturgis EM, Zafereo ME, Wei Q and
Li G: p14ARF genetic polymorphisms and susceptibility to second
primary malignancy in patients with index squamous cell carcinoma
of the head and neck. Cancer. 117:1227–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng TH, Hsu PK, Li AF, Hung IC, Huang MH
and Hsu HS: Correlation of p53, MDM2 and p14(ARF) protein
expression in human esophageal squamous cell carcinoma. J Cancer
Res Clin Oncol. 135:1577–1582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin TH, Kuo HC, Chou HP and Lu FJ:
Berberine enhances inhibition of glioma tumor cell migration and
invasiveness mediated by arsenic trioxide. BMC Cancer. 8:582008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsia DA, Mitra SK, Hauck CR, Streblow DN,
Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, et al:
Differential regulation of cell motility and invasion by FAK. J
Cell Biol. 160:753–767. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aplin AE, Howe AK and Juliano RL: Cell
adhesion molecules, signal transduction and cell growth. Curr Opin
Cell Biol. 11:737–744. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnson JP: Cell adhesion molecules in the
development and progression of malignant melanoma. Cancer
Metastasis Rev. 18:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cell induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Derycke LD and Bracke ME: N-cadherin in
the spotlight of cell-cell adhesion, differentiation,
embryogenesis, invasion and signaling. Int J Dev Biol. 48:463–476.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bottazzi ME, Zhu X, Böhmer RM and Assoian
RK: Regulation of p21(cip1) expression by growth factors and the
extracellular matrix reveals a role for transient ERK activity in
G1 phase. J Cell Biol. 146:1255–1264. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roovers K and Assoian RK: Integrating the
MAP kinase signal into the G1 phase cell cycle machinery.
Bioessays. 22:818–826. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sherr CJ and Roberts JM: Inhibitors of
mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149–1163.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Torii S, Yamamoto T, Tsuchiya Y and
Nishida E: ERK MAP kinase in G cell cycle progression and cancer.
Cancer Sci. 97:697–702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang M, Li J, Wang L, Tian Z, Zhang P, Xu
Q, Zhang C, Wei F and Chen W: Prognostic significance of p21, p27
and survivin protein expression in patients with oral squamous cell
carcinoma. Oncol Lett. 6:381–386. 2013.PubMed/NCBI
|
|
20
|
Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo
SF, Sun CC, Huang CC, Pang JH, Flanagan JN, Takano M, et al:
MART-10, a novel vitamin D analog, inhibits head and neck squamous
carcinoma cells growth through cell cycle arrest at G0/G1 with
upregulation of p21 and p27 and downregulation of telomerase. J
Steroid Biochem Mol Biol. 138:427–434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ling Y and Zhang C, Shen R, Xu Y, Zhu C,
Lu M, Liu Y and Zhang C: p14ARF repression induced by promoter
methylation associated with metastasis in esophageal squamous cell
carcinoma. Dis Esophagus. 27:182–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reed JA, Bales E, Xu W, Okan NA,
Bandyopadhyay D and Medrano EE: Cytoplasmic localization of the
oncogenic protein Ski in human cutaneous melanomas in vivo:
Functional implications for transforming growth factor beta
signaling. Cancer Res. 61:8074–8078. 2001.PubMed/NCBI
|
|
23
|
Reed JA, Lin Q, Chen D, Mian IS and
Medrano EE: SKI pathways inducing progression of human melanoma.
Cancer Metastasis Rev. 24:265–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Akkiprik M, Hu L, Sahin A, Hao X and Zhang
W: The subcellular localization of IGFBP5 affects its cell growth
and migration functions in breast cancer. BMC Cancer. 9:1032009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thang ND, Nghia PT, Kumasaka MY, Yajima I
and Kato M: Treatment of vemurafenib-resistant SKMEL-28 melanoma
cells with paclitaxel. Asian Pac J Cancer Prev. 16:699–705. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Juszczynski P, Kutok JL, Li C, Mitra J,
Aguiar RC and Shipp MA: BAL1 and BBAP are regulated by a gamma
interferon-responsive bidirectional promoter and are overexpressed
in diffuse large B-cell lymphomas with a prominent inflammatory
infiltrate. Mol Cell Biol. 26:5348–5359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis
J and Shipp MA: BAL1 and Its Partner E3 ligase, BBAP, link Poly
(ADP-Ribose) activation, ubiquitylation, and double-strand DNA
repair independent of ATM, MDC1, and RNF8. Mol Cell Biol.
33:845–857. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnson DP, Spitz GS, Tharkar S, Quayle
SN, Shearstone JR, Jones S, McDowell ME, Wellman H, Tyler JK,
Cairns BR, et al: HDAC1,2 inhibition impairs EZH2- and BBAP-
mediated DNA repair to overcome chemoresistance in EZH2
gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget.
6:4863–4887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bachmann SB, Frommel SC, Camicia R,
Winkler HC, Santoro R and Hassa PO: DTX3L and ARTD9 inhibit IRF1
expression and mediate in cooperation with ARTD8 survival and
proliferation of metastatic prostate cancer cells. Mol Cancer.
13:1252014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L and Zou W: Inhibition of integrin
β1 decreases the malignancy of ovarian cancer cells and potentiates
anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med
Rep. 12:7869–7876. 2015.PubMed/NCBI
|
|
31
|
Zhang L, Wang D, Jiang W, Edwards D, Qiu
W, Barroilhet LM, Rho JH, Jin L, Seethappan V, Vitonis A, et al:
Activated networking of platelet activating factor receptor and
FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk
ovarian epithelium. Reprod Biol Endocrinol. 8:742010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee MH, Kachroo P, Pagano PC, Yanagawa J,
Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM and Lee
JM: Combination treatment with Apricoxib and IL-27 enhances
inhibition of epithelial-mesenchymal transition in human lung
cancer cells through a STAT1 dominant pathway. J Cancer Sci Ther.
6:468–477. 2014.PubMed/NCBI
|
|
33
|
Kachroo P, Lee MH, Zhang L, Baratelli F,
Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, et al:
IL-27 inhibits epithelial-mesenchymal transition and angiogenic
factor production in a STAT1-dominant pathway in human non-small
cell lung cancer. J Exp Clin Cancer Res. 32:972013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Zhang Y, Yun H, Lai R and Su M:
Correlation of STAT1 with apoptosis and cell-cycle markers in
esophageal squamous cell carcinoma. PLoS One. 9:e1139282014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun Y, Yang S, Sun N and Chen J:
Differential expression of STAT1 and p21 proteins predicts
pancreatic cancer progression and prognosis. Pancreas. 43:619–623.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu W, Dong M, Bo L, Li C, Liu Q, Li Z and
Jin F: Epigallocatechin-3-gallate suppresses alveolar epithelial
cell apoptosis in seawater aspiration-induced acute lung injury via
inhibiting STAT1-caspase-3/p21 associated pathway. Mol Med Rep.
13:829–836. 2016.PubMed/NCBI
|
|
37
|
Li W, Fan J, Banerjee D and Bertino JR:
Overexpression of p21(waf1) decreases G2-M arrest and apoptosis
induced by paclitaxel in human sarcoma cells lacking both p53 and
functional Rb protein. Mol Pharmacol. 55:1088–1093. 1999.PubMed/NCBI
|
|
38
|
Héliez C, Baricault L, Barboule N and
Valette A: Paclitaxel increases p21 synthesis and accumulation of
its AKT-phosphorylated form in the cytoplasm of cancer cells.
Oncogene. 22:3260–3268. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferreira P, Oliveira MJ, Beraldi E, Mateus
AR, Nakajima T, Gleave M, Yokota J, Carneiro F, Huntsman D, Seruca
R and Suriano G: Loss of functional E-cadherin renders cells more
resistant to the apoptotic agent taxol in vitro. Exp Cell Res.
310:99–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T,
Pecot CV, Zand B, Liu T, Huang J, Jennings NB, et al: Role of focal
adhesion kinase in regulating YB-1-mediated paclitaxel resistance
in ovarian cancer. J Natl Cancer Inst. 105:1485–1495. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Smalley KS: PLX-4032, a small-molecule
B-Raf inhibitor for the potential treatment of malignant melanoma.
Curr Opin Investig Drugs. 11:699–706. 2010.PubMed/NCBI
|
|
42
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bollag G, Tsai J, Zhang J, Zhang C,
Ibrahim P, Nolop K and Hirth P: Vemurafenib: The first drug
approved for BRAF-mutant cancer. Nat Rev Drug Discov. 11:873–886.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
